RATIONALE: Improved understanding of the lung microbiome in HIV-infected individuals could lead to better strategies for diagnosis, therapy, and prophylaxis of HIV-associated pneumonias. Differences in the oral and lung microbiomes in HIV-infected and HIV-uninfected individuals are not well defined. Whether highly active antiretroviral therapy influences these microbiomes is unclear. OBJECTIVES: We determined whether oral and lung microbiomes differed in clinically healthy groups of HIV-infected and HIV-uninfected subjects. METHODS: Participating sites in the Lung HIV Microbiome Project contributed bacterial 16S rRNA sequencing data from oral washes and bronchoalveolar lavages (BALs) obtained from HIV-uninfected individuals (n = 86), HIV-infected individuals who were treatment naive (n = 18), and HIV-infected individuals receiving antiretroviral therapy (n = 38). MEASUREMENTS AND MAIN RESULTS: Microbial populations differed in the oral washes among the subject groups (Streptococcus, Actinomyces, Rothia, and Atopobium), but there were no individual taxa that differed among the BALs. Comparison of oral washes and BALs demonstrated similar patterns from HIV-uninfected individuals and HIV-infected individuals receiving antiretroviral therapy, with multiple taxa differing in abundance. The pattern observed from HIV-infected individuals who were treatment naive differed from the other two groups, with differences limited to Veillonella, Rothia, and Granulicatella. CD4 cell counts did not influence the oral or BAL microbiome in these relatively healthy, HIV-infected subjects. CONCLUSIONS: The overall similarity of the microbiomes in participants with and without HIV infection was unexpected, because HIV-infected individuals with relatively preserved CD4 cell counts are at higher risk for lower respiratory tract infections, indicating impaired local immune function.
RATIONALE: Improved understanding of the lung microbiome in HIV-infected individuals could lead to better strategies for diagnosis, therapy, and prophylaxis of HIV-associated pneumonias. Differences in the oral and lung microbiomes in HIV-infected and HIV-uninfected individuals are not well defined. Whether highly active antiretroviral therapy influences these microbiomes is unclear. OBJECTIVES: We determined whether oral and lung microbiomes differed in clinically healthy groups of HIV-infected and HIV-uninfected subjects. METHODS: Participating sites in the Lung HIV Microbiome Project contributed bacterial 16S rRNA sequencing data from oral washes and bronchoalveolar lavages (BALs) obtained from HIV-uninfected individuals (n = 86), HIV-infected individuals who were treatment naive (n = 18), and HIV-infected individuals receiving antiretroviral therapy (n = 38). MEASUREMENTS AND MAIN RESULTS: Microbial populations differed in the oral washes among the subject groups (Streptococcus, Actinomyces, Rothia, and Atopobium), but there were no individual taxa that differed among the BALs. Comparison of oral washes and BALs demonstrated similar patterns from HIV-uninfected individuals and HIV-infected individuals receiving antiretroviral therapy, with multiple taxa differing in abundance. The pattern observed from HIV-infected individuals who were treatment naive differed from the other two groups, with differences limited to Veillonella, Rothia, and Granulicatella. CD4 cell counts did not influence the oral or BAL microbiome in these relatively healthy, HIV-infected subjects. CONCLUSIONS: The overall similarity of the microbiomes in participants with and without HIV infection was unexpected, because HIV-infected individuals with relatively preserved CD4 cell counts are at higher risk for lower respiratory tract infections, indicating impaired local immune function.
Entities:
Keywords:
HIV infection; bronchoalveolar lavage; bronchoscopy; lung; microbiome
Authors: Yvonne J Huang; Emily S Charlson; Ronald G Collman; Sandra Colombini-Hatch; Fernando D Martinez; Robert M Senior Journal: Am J Respir Crit Care Med Date: 2013-06-15 Impact factor: 21.405
Authors: Homer L Twigg; Alison Morris; Elodie Ghedin; Jeffrey L Curtis; Gary B Huffnagle; Kristina Crothers; Thomas B Campbell; Sonia C Flores; Andrew P Fontenot; James M Beck; Laurence Huang; Susan Lynch; Kenneth S Knox; George Weinstock Journal: Lancet Respir Med Date: 2013-07-08 Impact factor: 30.700
Authors: Aurélien Trompette; Eva S Gollwitzer; Koshika Yadava; Anke K Sichelstiel; Norbert Sprenger; Catherine Ngom-Bru; Carine Blanchard; Tobias Junt; Laurent P Nicod; Nicola L Harris; Benjamin J Marsland Journal: Nat Med Date: 2014-01-05 Impact factor: 53.440
Authors: Rachel M Presti; Scott A Handley; Lindsay Droit; Mahmoud Ghannoum; Mark Jacobson; Caroline H Shiboski; Jennifer Webster-Cyriaque; Todd Brown; Michael T Yin; Edgar T Overton Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Derrick R Samuelson; Robert W Siggins; Sanbao Ruan; Angela M Amedee; Jiusong Sun; Quan Karen Zhu; Wayne A Marasco; Christopher M Taylor; Meng Luo; David A Welsh; Judd E Shellito Journal: Alcohol Date: 2018-09-11 Impact factor: 2.405
Authors: Chandresh Nanji Ladva; Rachel Golan; Roby Greenwald; Tianwei Yu; Stefanie Ebelt Sarnat; W Dana Flanders; Karan Uppal; Douglas I Walker; ViLinh Tran; Donghai Liang; Dean P Jones; Jeremy A Sarnat Journal: J Breath Res Date: 2017-12-06 Impact factor: 3.262
Authors: Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris Journal: Free Radic Biol Med Date: 2016-12-16 Impact factor: 7.376
Authors: Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg Journal: Chest Date: 2017-04-17 Impact factor: 9.410
Authors: Derrick R Samuelson; Ellen L Burnham; Vincent J Maffei; R William Vandivier; Eugene E Blanchard; Judd E Shellito; Meng Luo; Christopher M Taylor; David A Welsh Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-31 Impact factor: 5.464